logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5667.produseast1
Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article
|
Research
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, 
Journal Article
|
Research
Journal Article
|
Short Report
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Research & Publication Resources
|
Research Protocol
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Hayrapetyan A, 
et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A,  et al.
2014-02-01 • International Journal of Tuberculosis and Lung Disease
2014-02-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).

OBJECTIVE
To identify factors related to default from DR-TB treatment in Yereva...

Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia

Bastard M, Sanchez-Padilla E, Hewison CCH, Hayrapetyan A, Khurkhumal S,  et al.
2014-10-13 • Journal of Infectious Diseases
2014-10-13 • Journal of Infectious Diseases
The success of the current treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is poor partly due to a high defaulter rate. Many studies explored predictors of poor outcomes,...

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N,  et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...

High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study

Huerga H, Sanchez-Padilla E, Melikyan N, Atshemyan H, Ulumyan A,  et al.
2018-12-06 • Archives of Disease in Childhood
2018-12-06 • Archives of Disease in Childhood
OBJECTIVE
We aimed to measure the prevalence and incidence of latent tuberculosis infection (LTBI) and tuberculosis (TB) disease in children in close contact with patients with drug-...

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J,  et al.
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...

Performance of decentralised facilities in tuberculosis case notification and treatment success in Armenia

Davtyan K, Zachariah R, Davtyan H, Ramsay AR, Denisiuk O,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
We assessed the performance of decentralised tuberculosis (TB) out-patient centres in tuberculosis (TB) case notification and treatment success in Armenia. An average threshold case noti...

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH,  et al.
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M,  et al.
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...

Field-testing a pedagogical evaluation system for assessing skills of patients with drug-resistant tuberculosis

Blasco P, Hewison CCH, Crozet C
2015-06-01 • Educ Ther Patient/Ther Patient Educ
2015-06-01 • Educ Ther Patient/Ther Patient Educ
INTRODUCTION
As part of a programme providing care for patients with drug-resistant tuberculosis (DR-TB) in Armenia, participation in therapeutic patient education (TPE) is proposed ...

Detecting tuberculosis: rapid tools but slow progress

England K, Masini T, Fajardo E
2019-09-21 • Public Health Action
2019-09-21 • Public Health Action
The World Health Organization (WHO) currently recommends Xpert® MTB/RIF as the initial test for all people with presumptive tuberculosis (TB). A number of challenges have been reported, ...

Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis

Mohr E, Ferlazzo G, Hewison CCH, De Azevedo V, Isaakidis P
2019-05-01 • Lancet Infectious Diseases
2019-05-01 • Lancet Infectious Diseases
Here we report on the final outcomes for the cohort of 28 patients from Armenia, India, and South Africa who initiated regimens containing the combination of bedaquiline and delamanid fr...

What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?

Bastard M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, Khurkhumal S,  et al.
2019-10-01 • International Journal of Tuberculosis and Lung Disease
2019-10-01 • International Journal of Tuberculosis and Lung Disease
INTRODUCTION
Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

Bonnet MMB, Bastard M, du Cros PAK, Khamraev AK, Kimenye K,  et al.
2016-02-01 • International Journal of Tuberculosis and Lung Disease
2016-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not avail...

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A,  et al.
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...

Social support programme for tuberculosis patients in Armenia: perceptions of patients and doctors

Davtyan K, Aghabekyan S, Davtyan H, Margaryan T, Zachariah R,  et al.
2016-01-01 • Public Health Panorama
2016-01-01 • Public Health Panorama
BACKGROUND AND OBJECTIVE
Adherence to treatment is an important factor for the successful treatment of tuberculosis (TB). Many countries have introduced incentive mechanisms to enhan...